肾移植受者使用抗胸腺细胞球蛋白（ATGAM）的延长治疗。
Extended treatment with antithymocyte globulin (ATGAM) in renal allograft recipients.
作者信息
Wechter W J, Morrell R M, Bergan J, Rosenberg J C, Turcotte J, Schultz J R
出版信息
Transplantation. 1979 Nov;28(5):365-7. doi: 10.1097/00007890-197911000-00003.
Twenty renal allograft recipients were treated with antithymocyte globulin (ATGAM; ATG) for up to 16 weeks in addition to azathioprine and prednisone, while 20 controls received no ATG. The ATG group showed a lower incidence of first rejection episodes during the first month after transplantation, and also a better functional graft survival rate up to 2 years after transplantation. The results in this early ATG trial were better than those in subsequent trials which used 14-day treatment regimens. Longer treatment deserves another look.
20例肾移植受者除接受硫唑嘌呤和泼尼松治疗外，还接受抗胸腺细胞球蛋白（ATGAM；ATG）治疗长达16周，而20例对照者未接受ATG治疗。ATG组在移植后第一个月首次排斥反应的发生率较低，并且在移植后长达2年的时间里移植肾功能存活率也更高。这项早期ATG试验的结果优于随后采用14天治疗方案的试验结果。更长时间的治疗值得重新审视。
Zotero 插件